Long Focus Capital Management LLC Purchases 260,594 Shares of Sight Sciences, Inc. (NASDAQ:SGHT)

Long Focus Capital Management LLC lifted its position in shares of Sight Sciences, Inc. (NASDAQ:SGHT) by 86.9% in the second quarter, HoldingsChannel reports. The fund owned 560,594 shares of the company’s stock after buying an additional 260,594 shares during the period. Long Focus Capital Management LLC’s holdings in Sight Sciences were worth $3,739,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in SGHT. UBS Group AG boosted its stake in shares of Sight Sciences by 20,282.6% in the 4th quarter. UBS Group AG now owns 2,895,958 shares of the company’s stock valued at $14,943,000 after purchasing an additional 2,881,750 shares during the last quarter. Vanguard Group Inc. grew its holdings in Sight Sciences by 5.5% during the 1st quarter. Vanguard Group Inc. now owns 1,556,450 shares of the company’s stock worth $8,218,000 after acquiring an additional 81,768 shares during the period. Jacobs Levy Equity Management Inc. grew its holdings in Sight Sciences by 25.5% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 377,057 shares of the company’s stock worth $1,991,000 after acquiring an additional 76,549 shares during the period. RTW Investments LP bought a new stake in shares of Sight Sciences during the 4th quarter valued at $850,000. Finally, Bank of New York Mellon Corp boosted its position in shares of Sight Sciences by 70.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 102,461 shares of the company’s stock worth $683,000 after purchasing an additional 42,383 shares during the last quarter. Institutional investors and hedge funds own 55.51% of the company’s stock.

Insider Activity at Sight Sciences

In other Sight Sciences news, CFO Alison Bauerlein sold 10,497 shares of the business’s stock in a transaction that occurred on Tuesday, July 2nd. The stock was sold at an average price of $6.21, for a total transaction of $65,186.37. Following the transaction, the chief financial officer now owns 402,685 shares of the company’s stock, valued at approximately $2,500,673.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Sight Sciences news, CEO Paul Badawi sold 12,569 shares of the company’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $6.42, for a total value of $80,692.98. Following the transaction, the chief executive officer now directly owns 5,738,160 shares in the company, valued at $36,838,987.20. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Alison Bauerlein sold 10,497 shares of the company’s stock in a transaction dated Tuesday, July 2nd. The shares were sold at an average price of $6.21, for a total transaction of $65,186.37. Following the completion of the transaction, the chief financial officer now owns 402,685 shares in the company, valued at approximately $2,500,673.85. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 34,774 shares of company stock valued at $219,243. 28.90% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on SGHT shares. Lake Street Capital started coverage on Sight Sciences in a report on Wednesday, August 21st. They issued a “buy” rating and a $10.00 price objective for the company. Morgan Stanley boosted their price objective on shares of Sight Sciences from $5.40 to $6.50 and gave the company an “equal weight” rating in a report on Monday, July 15th. Needham & Company LLC reissued a “hold” rating on shares of Sight Sciences in a research report on Friday, August 2nd. Finally, Citigroup lifted their target price on Sight Sciences from $6.00 to $6.50 and gave the stock a “neutral” rating in a report on Wednesday, July 10th. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, Sight Sciences has a consensus rating of “Hold” and an average price target of $7.25.

Sight Sciences Stock Up 2.2 %

NASDAQ:SGHT opened at $6.57 on Friday. Sight Sciences, Inc. has a 52-week low of $1.04 and a 52-week high of $8.45. The company has a debt-to-equity ratio of 0.33, a quick ratio of 10.50 and a current ratio of 11.01. The stock has a 50-day simple moving average of $6.67 and a 200 day simple moving average of $6.17. The company has a market cap of $326.90 million, a PE ratio of -5.87 and a beta of 2.72.

Sight Sciences (NASDAQ:SGHT) last announced its earnings results on Thursday, August 1st. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.06. Sight Sciences had a negative net margin of 65.90% and a negative return on equity of 45.68%. The business had revenue of $21.37 million during the quarter, compared to analysts’ expectations of $21.32 million. During the same quarter in the prior year, the company posted ($0.30) earnings per share. On average, sell-side analysts expect that Sight Sciences, Inc. will post -1 EPS for the current fiscal year.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.